IgG-induced experimental immune synovitis: hormonal modulation of in vitro splenic immune responses to homologous antigens.
The effect of oestrogen or anti-oestrogen administration on gross pathology and in vitro cell-mediated immune responses to homologous IgG, native and denatured interstitial collagens and PPD was studied in an IgG-induced rabbit model of immune synovitis. During induction of synovitis, rabbits were administered oestradiol valerate (0.075 mg/kg/day) or tamoxifen, an anti-oestrogen (2.0 mg/kg/day, high dose or 0.5 mg/kg/day, low dose) or placebo injections. Low dose tamoxifen administration was associated with significant improvement P less than 0.05 in immune synovitis with regard to gross pathology, when compared to placebo and the oestradiol treatment group. High dose tamoxifen treatment was not associated with significant improvement in observed synovitis. With regard to cell-mediated immune responses, spleen cells derived from immune synovitis rabbits were observed to increase 3H-thymidine uptake on incubation with native or denatured homologous collagens. Modulation of these immune responses to antigens was observed in anti-oestrogen treated rabbits with immune synovitis. In vitro cell-mediated immune responses to denatured type I, II and III collagens, PPD, as well as native type II and III collagens were not observed in the low dose tamoxifen treatment group. However, in vitro immune responses to these antigens were observed in spleen cell cultures from immune synovitis rabbits treated with either high dose tamoxifen or oestradiol valerate. The data suggest that in vivo anti-oestrogen administration can modulate the in vitro cell-mediated immune response to connective tissue constituents observed in immune synovitis. Concomitant with reduced immune responses is a significant reduction in the observed lesions of the inflammatory response.
D000818:Animals; D000941:Antigens / Q000276:immunology*; D002460:Cell Line; D003094:Collagen / Q000276:immunology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D007111:Immunity, Cellular / Q000187:drug effects; D007074:Immunoglobulin G / Q000276:immunology*; D011817:Rabbits; D013154:Spleen / Q000276:immunology* / Q000378:metabolism; D013585:Synovitis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D013629:Tamoxifen / Q000627:therapeutic use*; D013936:Thymidine / Q000378:metabolism; D014373:Tuberculin / Q000276:immunology
D000941:Antigens; D007074:Immunoglobulin G; D014373:Tuberculin; D013629:Tamoxifen; D004958:Estradiol; D003094:Collagen; D013936:Thymidine